$PASG

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

The mean of analysts' price targets for Passage Bio (PASG) points to a 1415.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Aug 15, 2025, 1:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 16, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade — source image
Decision brief

The 30-second read

$PASGBullishMed
01

Why it matters

The optimistic analyst outlook could lead to increased trading volume and upward price movement, but investors should remain cautious due to the speculative nature of biotech stocks.

02

Market read

The news is highly relevant to biotech investors and traders, especially those focusing on gene therapy companies.

03

What to watch

Potential regulatory hurdles, clinical trial failures, or broader market downturns could significantly impact the stock's performance, counteracting analyst optimism.

Timing: short to medium term (next 1-6 months)

Background

Passage Bio is a biotech firm focused on gene therapies, with recent analyst reports highlighting strong earnings estimate revisions and a high consensus on future growth.

Company-level read

Ticker impact

$PASGBullishMedium confidence
Context

High relevance due to analyst consensus on significant upside potential.

Expected impact

Potential for a sharp increase in stock price, possibly exceeding 1000% in the short to medium term, contingent on market conditions and execution of company milestones.

Evidence & confidence

While the consensus among analysts indicates a strong upside, historical effectiveness of such price targets is limited, and actual market reactions depend on broader factors including execution risks and market sentiment.

Market effects

Positive sentiment towards biotech and life sciences sectors, potentially boosting related stocks.

Limited regional impact; primarily relevant to US biotech markets.

Moderate; biotech sector trends can influence global healthcare markets.

Counterpoint

The projected 1415% upside may be overly optimistic; actual stock performance could be limited or negative if company milestones are missed or market conditions deteriorate.

Key entities

  • Passage Bio

    Biotech firm specializing in gene therapies for rare diseases.

  • Analysts' Consensus

    Aggregated analyst price targets indicating a 1415.2% upside.

Related articles

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.